EASTONBIOPHARMACEUTICALS(SH:688513) Hua Yuan Zheng Quan·2026-02-09 08:00Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4][47]. Core Viewpoints - The pharmaceutical market showed a slight increase of 0.14% from February 2 to February 6, with a relative outperformance of 1.47% compared to the CSI 300 index. The report suggests focusing on strong fundamental innovative drug stocks and highlights the potential for recovery in the innovative drug sector [5][16]. - The report emphasizes the significance of molecular glue technology in expanding the druggable target space, particularly for "undruggable targets," and suggests monitoring the progress of related drugs from Yuandong Biotech [3][8]. - The report outlines a positive outlook for the pharmaceutical industry in 2026, driven by technological innovation and performance/valuation recovery, with a focus on innovative drugs, AI medical technology, and the aging population's healthcare needs [36][37]. Summary by Sections Market Performance - The pharmaceutical index increased by 0.14% during the specified week, with 253 stocks rising and 206 falling. Top gainers included Guangshengtang (+29.83%) and Haixiang Pharmaceutical (+18.64%), while major losers included Changshan Pharmaceutical (-15.78%) and Shuanglu Pharmaceutical (-13.95%) [5][16][17][18]. Molecular Glue Technology - Molecular glue targets undruggable proteins, with only about 3.5% of human proteins confirmed as druggable. The report highlights Yuandong Biotech's advancements in this area, particularly their product HP-001, which shows promising clinical data and potential as a "Best-in-Class" treatment [8][12][13]. Investment Recommendations - The report recommends focusing on innovative drug companies such as Heng Rui Pharmaceutical, China Biologic Products, and Yuandong Biotech, as well as companies involved in AI medical technology and healthcare for the aging population [36][39]. Industry Trends - The report identifies key trends such as the acceleration of the aging population, the growth of chronic disease demand, and the increasing importance of commercial insurance in the healthcare payment system. It also notes the potential for new growth drivers from AI and brain-computer interface technologies [36][37]. Valuation Insights - As of February 6, 2026, the overall PE valuation for the pharmaceutical sector is 37.31X, indicating a relatively low historical position. The report suggests that various sub-sectors have differing valuation levels, with some being relatively high and others low [25][32]. Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve in 2026, with a focus on innovative drugs and technologies. It suggests that structural growth opportunities will emerge, particularly in the context of the global healthcare landscape [36][37].